Sankyo Parke Davis olmesartan medoxil
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Firm plans to file an NDA by end of August for olmesartan medoxil (CS-866), an oral angiotensin-II receptor antagonist for treatment of hypertensio